Deltex Medical Group plc (AIM: DEMG), the global leader in Oesophageal Doppler Monitoring (“ODM”) has announced that its wholly owned UK subsidiary, Deltex Medical Limited, has been awarded a grant…
Deltex Medical Receives Innovative Technology Contract From Major US Healthcare Consultancy
Deltex Medical Group plc (AIM: DEMG), the global leader in oesophageal Doppler monitoring, has received an Innovative Technology contract from Vizient, Inc., the largest member-driven healthcare performance improvement company in the…
Oesophageal Doppler Features Strongly in Updated Cancer Surgery Guidance
The UK’s National Institute for Health and Care Excellence (NICE) has updated its guidance for practitioners in the management of colorectal cancer. NICE publishes it’s so-called “pathways” in order to…
Deltex Medical’s Haemodynamic Management Tools at Euroanaesthesia
This weekend sees Vienna hosting the annual Euroanaesthesia event, recognised worldwide as one of the most important and influential congresses in anaesthesiology. With over 6000 international delegates and 100+ exhibitors from…
Deltex CEO Andy Mears to present at Turner Pope investment evening, May 13
Deltex Medical Group plc (AIM: DEMG), the global leader in Oesophageal Doppler Monitoring (“ODM”), is pleased to announce that Andy Mears, the Company’s Chief Executive Officer, will be presenting at an investor evening…
Deltex Medical 2018 Results
Deltex Medical Group plc (AIM: DEMG), the global leader in oesophageal Doppler monitoring, has announced its audited results for the year ended 31 December 2018. Find the link to the…
Pre-Close Statement and Trading Update
Deltex Medical Group plc (AIM: DEMG), the global leader in oesophageal Doppler monitoring, has published a pre-close statement in relation to the year ended 31 December 2018. The Group has…
NICE Recommends ODM in Trauma Patients with Major Haemorrhaging
The UK’s National Institute for Health and Care Excellence (NICE) publishes guidance on many aspects of patient care. These documents are often collated into treatment pathways, bringing together everything NICE…
29 Years and Counting: Mears and the Haemodynamic Management Mission
Speaking from the heart, Andy Mears CEO of Deltex says “Thanks to LinkedIn for kindly pointing out that I am celebrating 29 years at Deltex Medical this month. Thanks also…
Show Time for Deltex with US Launch of TrueVue at ASA
October 13th sees the start of this year’s Anesthesiology Society of America (ASA) annual congress in San Francisco. Deltex will be exhibiting at this major event (booth 1513), launching its…
